Saturday 7 November 2026
Export STLN’s income statement to Excel — free account
Starling Oncology, Inc.
STLN Healthcare Medical Care Facilities
Starling Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.7 million, up 27.8% from fiscal 2024.
- Revenue
- +24.3%
- EPS
- +7.14%
- Free cash flow
- +167.1%
- Total debt
- −4.82%
Quarter to September 2026, against a year earlier
3.51
3.19
−47.61%
Follow STLN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 5 | — |
| 999.19% | 775.91% | 214.12% | 143.21% | ||
| (35.93%) | (26.19%) | (21.47%) | (20.23%) | ||
ROIC |
(80.21%) | (63.75%) | (117.66%) | 0.00% | |
Return on Tangible Assets |
(115.51%) | (90.26%) | (81.31%) | (144.55%) | |
Average Days of Receivables |
43.07 | 39.76 | 41.46 | 35.77 | |
Free Cash Flow per Share |
(0.30) | (0.25) | (0.03) | 0.18 | |
Free Cash Flow |
(27.79) | (25.73) | (3.29) | 18.83 | |
Capital Expenditures |
(3.20) | (3.91) | (3.61) | (4.27) | |
| Other line items | |||||
Cash ROIC |
(29.17%) | (27.78%) | (3.42%) | 26.13% | |
Accounts Receivable Turnover |
9.31 | 10.00 | 9.58 | 10.27 | |
Accounts Payable Turnover |
12.63 | 12.04 | 10.40 | 0.00 | |
Inventory Turnover |
31.68 | 25.32 | 27.66 | 0.00 | |
Average Days of Payables |
36.96 | 37.54 | 44.44 | 0.00 | |
Days of Inventory on Hand |
14.45 | 19.14 | 14.75 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
21.00% | 19.86% | 18.98% | 19.07% | |
Share Based Compensation of Revenue |
0.91% | 0.88% | 0.87% | 0.87% | |
Interest Coverage |
(3.20) | (4.28) | (3.42) | (2.79) | |
Operating CF/Net income |
0.41 | 0.50 | (0.01) | (0.65) | |
Depreciation/Fixed assets |
1.43 | 1.07 | 1.10 | 0.00 | |
Capex/Depreciation |
(0.21) | (0.34) | (0.31) | 0.00 | |
Revenue per Share |
5.44 | 5.36 | 5.70 | 5.92 | |
Operating CF per Share |
(0.27) | (0.21) | 0.00 | 0.22 | |
Capex per Share |
(0.03) | (0.04) | (0.04) | (0.04) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 6 Nov 2026